MDMA-assisted therapy has produced some of the most striking results in modern psychiatry — for PTSD in particular. It works by softening fear just enough that a person can finally turn toward what happened, with two therapists beside them, and process it.
MDMA is a synthetic compound first made in 1912. It's an empathogen — it produces warmth, trust, and emotional openness. Therapists in the 1970s and '80s used it to help people talk about things they couldn't otherwise bear to, until it was made illegal in the mid-1980s.
Since then, organizations like MAPS have run rigorous clinical trials of MDMA-assisted therapy for PTSD — with results strong enough to put it on the doorstep of approval. This is about healing trauma in a therapeutic container, not recreation.
Trauma work usually fails because approaching the memory sets off overwhelming fear. MDMA changes that equation for a few hours.
It quiets the amygdala — the brain's fear alarm — so a traumatic memory can be approached without panic.
A rise in oxytocin and serotonin brings warmth and safety — with the therapists, and with oneself.
In that calmer, more open state, the mind can revisit and re-file the memory — the heart of trauma healing.
MDMA-assisted therapy isn't a pill you take and go home. It's built around preparation sessions, then long dosing sessions — often 6 to 8 hours with two trained therapists present the entire time — followed by integration sessions to make sense of what came up.
A typical course in the trials was around three dosing sessions spread over a couple of months, each wrapped in that therapeutic support. The relationship and the container are as important as the molecule.
You meet your two therapists, build trust, set intentions, and learn what to expect — before any medicine is involved.
You take the dose and settle in — often eyes closed with music. Warmth and safety build, and you turn toward the difficult material with both therapists beside you the whole time.
Two therapists presentYou process what surfaced and weave it into daily life — where the real, lasting change happens.
The trial protocol was around three dosing sessions over a couple of months, each wrapped in preparation and integration.
A rare felt sense of safety that lets them approach memories they've avoided for years.
Meeting themselves — and their trauma — with warmth instead of shame or fear.
Revisiting what happened and having it feel different afterward — less charged, more integrated.
A deep sense of trust and closeness with the therapists holding the space.
In trials, many no longer met the criteria for PTSD months later — the change held.
The days right after can be tender; integration and rest carry it into something lighter.
MDMA is still a Schedule I substance in the U.S. MDMA-assisted therapy has moved through advanced clinical trials and been submitted for FDA approval, but it is not yet a legally available treatment. That's why, for now, this page is educational.
The therapy container is the safeguard. In a proper program, MDMA-assisted therapy is well-tolerated; its risks come from unscreened settings, mixing with certain medications, and going it alone.
MDMA-assisted therapy isn't legally available yet, so it's not in our network — but we're happy to help you understand it, the research, and the legitimate options that exist today.
Speak With An Advisor →No. Phase-3 trials reported remission in a majority of participants, but the FDA declined approval in 2024 and asked for further study.
PTSD is the primary indication studied.
Two or three MDMA sessions with therapists, spaced weeks apart, inside a course of preparation and integration therapy.
Through clinical trials and a small number of regulated programs abroad; we keep the vetted options current.
